IceCure Medical (ICCM) announced it is in continued discussions with the U.S. FDA regarding its De Novo marketing authorization request for ProSense in early-stage low risk breast cancer with endocrine therapy. The company now expects the FDA’s marketing authorization decision to be reached after the first quarter of 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure’s ProSense® Cryoablation Showcased at St. Gallen Breast Cancer Conference
- IceCure Medical Expands Global Patent Portfolio with New Cryogenic Pump Approval in China
- IceCure Medical receives Notice of Allowance from CNIPA
- IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study
- IceCure Medical Seeks Israeli Approval for Advanced Cryoablation System